PPARG and type 2 diabetes mellitus: The best characterized PPARγ agonistsare the TZDs including pioglitazone and rosiglitazone which are Food and DrugAdministration (FDA) approved for treatment of type II diabetes andtroglitazone, which was withdrawn in 2000.